{"name":"Aptose Biosciences Inc.","slug":"aptose-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":11341000,"netIncome":-25468000,"cash":935000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Virulizin®","genericName":"Virulizin®","slug":"virulizin","indication":"Ovarian cancer (in combination with chemotherapy)","status":"phase_3"}]}],"pipeline":[{"name":"Virulizin®","genericName":"Virulizin®","slug":"virulizin","phase":"phase_3","mechanism":"Virulizin is an oncolytic virus therapy that selectively infects and destroys cancer cells while sparing normal tissue.","indications":["Ovarian cancer (in combination with chemotherapy)","Other solid tumors (investigational)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOT2VSVWptZE5LRnlQTnJ5ZU9XSW1OMmxEMGFPR0RNdmVEUnVva09VQTNYdlo2R0RDWnNLWW04b0ZMZzN6UmZYOTVPYlYwRDZTeXNQRzdrMDBoalppY0RURl90TGV4VF9WNkZNT2tqUTZNd2FGbllUQlFJbXlfS0lfRlVkXzZubGxzU25Uc1NQZkgxQWZHaGljb1otRlowZHlBLUZmSHYzUkoxN3UwekxV?oc=5","date":"2026-03-31","type":"deal","source":"Stock Titan","summary":"Hanmi to acquire Aptose Biosciences (APTOF) in C$2.41-per-share cash deal - Stock Titan","headline":"Hanmi to acquire Aptose Biosciences (APTOF) in C$2.41-per-share cash deal","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNOWpiV0MwNWtGNUZHQjBXdWhoVE5aYkNocUR0UGgzbE5VWk80MUtKSS1vcWlNVXVzV1RPRFZFSGxDRlBLQmZJOS1MT3ZXdHRHNFgweEpWU1c5ZENzOW9neVZybU9Ec0tGZFNVTXdIX1N3YmgweDV0eE03OU5VU0d1VGFaYm9GU05yTHdHVTN6TFJ3NGFLNUtQZXdlUVJQWFo4YXY4NVFuMV9sdmZqVm9PRlRINEtCWjVOY0Jxbzg3UGU0ZGw3eW1QSzRnVWJqZUxvcV9DQVNNOHVjNTJycVc0X1Q0bHFnejR0LVFv?oc=5","date":"2026-03-23","type":"pipeline","source":"Minichart","summary":"Glass Lewis Recommends Aptose Shareholders Vote FOR Hanmi Pharmaceutical Arrangement in 2026 Proxy Advisory Update - Minichart","headline":"Glass Lewis Recommends Aptose Shareholders Vote FOR Hanmi Pharmaceutical Arrangement in 2026 Proxy Advisory Update","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNdlY3cFVTQzhBZlE2ekNQUTRxUDdpZW11Z0ZqaHkyQTlCYnFNQS1xYWtWTzdCVHU4Ujd5Tkx3dXlkekcyWDBBOWVWSmR3WkM1SGRSUzNRRTJieGNSbUVUNjZiWGpCel9KOVJ3dUpvM21Md2NoV3pjNWdUcFdWa2NQZFp6Q2lmWFFQZ1ZLb1NxU1FJS2o3UWgtNm0xbDlOeS1keWxpdTlJX2JHNnpm?oc=5","date":"2026-03-19","type":"pipeline","source":"Yahoo Finance","summary":"Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical - Yahoo Finance","headline":"Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arran","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNdU5ZcUpidFdkOVBZazl2a1lSaW5hTFV4cWg1NnFwSlBrZEF3aXIwTTdrZURJaDFkMFBWeWcyMGE5Z0Q5dVhmeEk2N3JYRHJ6ZEdma253T1poMHRQVVJjUWx1LVVid09UMDJ1Nmotc2gwdjlrQmhRU2IyWW1lc3E0OGlRSC1rVFYxVzI3TUhWbFhxMVVsWWk0V0V2UHVMZkZXcjZqdnh2emw4V2ctOExRWEJCN21BMDdBTk9mY1NacWgzQWVpX0NCM2VkYW11eTZ3enJCTFBHNV9JRjd2d3BsZS1teWI?oc=5","date":"2026-03-19","type":"pipeline","source":"marketscreener.com","summary":"Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote \"FOR\" Proposed Plan of Arrangement with Hanmi Pharmaceutical - marketscreener.com","headline":"Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote \"FOR\" Proposed Plan of Arrangement","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBfU3NhcXBXbjlsUEw1X2xyamRtZ0xjbUw4emxpUVh2eFFqNV9LTXFYMm5XX3UxeW11TFo0d2lVTUhCQnEyQmh1VDNKTTVsakRIcF9iUGhEMWZtN2Y1TnBqUFJHSGw3X3B6Uk5ncm530gFyQVVfeXFMUHhnMkNYcXZaTURkQ0lrUFlMeGs0Z0Y0bVpXeHVSY09MenFKUVBkbDJsamxYZVl1UlhYQ1dLbXZ1WnlwWmVQZEFBeTF2ZTdaYXdmdUpHQU5JVVN0ODhiUm1Ha2tqa0x1NUY4TlFFR2pqTEFB?oc=5","date":"2026-02-26","type":"deal","source":"koreabiomed.com","summary":"Hanmi amends Aptose merger deal, pushes shareholder vote to March and adds $11.1 mil. in financing - koreabiomed.com","headline":"Hanmi amends Aptose merger deal, pushes shareholder vote to March and adds $11.1 mil. in financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQUHRZQXdTWmNqR0R2UzVLTWtnelpqbUVJTE81ZEF4UmdmQVBRSGFJSHpNTkZOMUxNaWVYZzdHbkNQZzRfcmY3eWRTSUlEMmNKY3puTzRMOFFoX0ppRjRIZUR1bGxWdFVhNFdFRC0waV9Hd3drcnJsUHFBbFZoa3c5R3RMNC1NOUkwWkktZjdUQzA0T1duaXlhWmNuU0FqTTRSd1FBZnMzbkR1TWt1UUNfeVo3bWZJbnhBT2thWGhJVVlHQ05vOHJmcDhlRnlxSm8zR2xIX1NDbTliT0UyLVJ3?oc=5","date":"2026-02-24","type":"deal","source":"TradingView","summary":"Aptose Biosciences Updates Hanmi Take-Private Deal and Secures $11.1 Million Facility - TradingView","headline":"Aptose Biosciences Updates Hanmi Take-Private Deal and Secures $11.1 Million Facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQdXlfdWxsby1MWDRqYnp2SnRlVVdBVlozVnVHdzRZbWdVNlBzRUVzY2NyQ1p5ZXd5UXdwbUhTM2YwV1hKYzI5T0NjaDlaRlB1bDU3anI0U1hEeHU4cUZsdDJWTnpFR2k4TlBLZU05Mi1wUDUyRzZVNTFWYThCRVZKQnpKWmN4YW9KZWh6M2UxNWpYTnFxanZmMXgzbEhWWjl3dHNUaldXTy16ZUp2ZmdMTXUxdnl6dDE5VlRDSE9oTDhBdlVWSmN2RG54Z050cjZURFo1SlRDYXdoTWN2ajZNbEhUZm40dWVCbGk4VE5ycFBBSFc2bW5ncnBXaEFCR21qbFl6M0tJTHNyeTFqWlVMZ2R1V3V4M2doNEJXWEgtZXZfUQ?oc=5","date":"2026-02-24","type":"pipeline","source":"GlobeNewswire","summary":"Aptose Biosciences Announces Amendment to Arrangement - GlobeNewswire","headline":"Aptose Biosciences Announces Amendment to Arrangement","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11341000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-25468000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":935000,"cashHistory":[],"totalAssets":10012000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}